{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T02:32:52Z","timestamp":1770604372372,"version":"3.49.0"},"reference-count":39,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"crossref","award":["24K12519"],"award-info":[{"award-number":["24K12519"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: In high-risk non-muscle-invasive bladder cancer (NMIBC), adjuvant therapies, such as intravesical Bacillus Calmette\u2013Gu\u00e9rin (BCG) instillation, are widely employed; however, BCG treatment poses challenges due to potential adverse effects and ongoing supply limitations. This study aimed to evaluate treatment patterns, therapeutic efficacy, incidence of adverse events, and clinical predictors of recurrence and progression in patients with high-grade pT1 urothelial carcinoma (HG-T1 UC) of the bladder. Methods: This retrospective cohort study included 204 patients diagnosed with HG-pT1 UC who underwent transurethral resection of bladder tumor (TURBT) at Toho University Sakura Medical Center between 2010 and 2021. Clinical data encompassing treatment modalities (BCG or intravesical chemotherapy), complications, and oncological outcomes were collected. Recurrence-Free Survival (RFS), Progression-Free Survival, and Cancer-Specific Survival were analyzed using Kaplan\u2013Meier analyses and multivariate regression models. Results: Maintenance BCG therapy was significantly associated with prolonged RFS compared to other treatments, including among \u2018very high-risk\u2019 patients. However, 52.4% of patients receiving BCG maintenance experienced adverse events, with dose reductions required in 59% of cases. Notably, recurrence rates did not significantly differ based on dose reduction or the total number of BCG instillations. Tumor multiplicity emerged as an independent risk factor for recurrence. Conclusions: Although maintenance BCG therapy remains essential for managing HG-T1 UC, especially in high-risk patients, treatment should be individualized due to concerns about tolerability and availability. The study results support the importance of personalized strategies based on risk stratification as outlined in clinical guidelines for preventing recurrence in NMIBC.<\/jats:p>","DOI":"10.3390\/cancers18030532","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T11:10:38Z","timestamp":1770376238000},"page":"532","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High Oncological Efficacy of BCG Maintenance Therapy for Primary High-Grade T1 Urothelial Carcinoma of the Bladder"],"prefix":"10.3390","volume":"18","author":[{"given":"Takahide","family":"Noro","sequence":"first","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-2490","authenticated-orcid":false,"given":"Naoto","family":"Kamiya","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Ishitsuka","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rino","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syota","family":"Iijima","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Sugizaki","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatoshi","family":"Somoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9423-7361","authenticated-orcid":false,"given":"Takanobu","family":"Utsumi","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Hiruta","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5838-114X","authenticated-orcid":false,"given":"Hiroyoshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","unstructured":"(2007, August 01). Ganjoho.jp. Available online: https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/cancer\/21_bladder.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10147-016-1048-z","article-title":"Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: A retrospective, multi-institutional, collaborative study","volume":"22","author":"Kamiya","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_5","unstructured":"European Association of Urology (2025, November 03). EAU Guidelines on Non-Muscle-Invasive Bladder Cancer 2025. Available online: https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Non-muscle-Invasive-BC-2025.pdf."},{"key":"ref_6","unstructured":"National Comprehensive Cancer Network (2025, November 03). NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer, Version 1.2025. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00345-024-04834-4","article-title":"Treatment patterns and prognosis in patients with Bacillus Calmette-Gu\u00e9rin-exposed high-risk non-muscle invasive bladder cancer: A real-world data analysis","volume":"42","author":"Nishimura","year":"2024","journal-title":"World J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.043","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Sylvester","year":"2009","journal-title":"Eur. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s10147-022-02127-7","article-title":"Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Gu\u00e9rin therapy for non-muscle-invasive bladder cancer: A comparative analysis of large real-world data","volume":"27","author":"Tomida","year":"2022","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_11","first-page":"446","article-title":"Side effects of Bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk superficial bladder cancer","volume":"41","author":"Brausi","year":"2002","journal-title":"Eur. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bju.15661","article-title":"Reduced-dose bacillus Calmette-Gu\u00e9rin (BCG) in an era of BCG shortage: Real-world experience from a tertiary cancer centre","volume":"130","author":"Lobo","year":"2022","journal-title":"BJU Int."},{"key":"ref_13","first-page":"45","article-title":"Interruption of BCG therapy for NMIBC during COVID-19 crisis, dilemma in its continuation: A review of available evidence and suggested management strategies","volume":"17","author":"Tosh","year":"2023","journal-title":"Curr. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high-risk superficial bladder cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00345-024-05410-6","article-title":"Oncological outcomes and prognostic implications of T1 histo-anatomic substaging in the management of high-Grade non-muscle invasive bladder cancer: Results from a large single centre series","volume":"43","author":"Finati","year":"2024","journal-title":"World J. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s10147-019-01581-0","article-title":"The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: Results from randomized 10-year extension trial","volume":"25","author":"Eroglu","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.25259\/Cytojournal_213_2024","article-title":"Computer-assisted scatter plot analysis of cell and nuclear areas distinguishes urothelial carcinoma in urine cytology specimens","volume":"8","author":"Hoshino","year":"2025","journal-title":"Cytojournal"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Yang, Z., Song, F., and Zhong, J. (2025). Urinary Biomarkers in Bladder Cancer: FDA-Approved Tests and Emerging Tools for Diagnosis and Surveillance. Cancers, 17.","DOI":"10.20944\/preprints202510.0625.v1"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/iju.15483","article-title":"Photodynamic diagnosis-assisted transurethral resection of bladder tumor for high-risk non-muscle invasive bladder cancer improves intravesical recurrence-free survival (BRIGHT study)","volume":"31","author":"Kawai","year":"2024","journal-title":"Int. J. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Russo, G.I., Sholklapper, T.N., Cocci, A., Broggi, G., Cacciola, A., Di Mauro, M., Cimino, S., Morgia, G., Kimura, S., and Shimizu, T. (2021). Performance of narrow band imaging and photodynamic diagnosis fluorescence imaging compared to white light cystoscopy in detecting non-muscle invasive bladder cancer: A systematic review and lesion-level diagnostic meta-analysis. Cancers, 13.","DOI":"10.3390\/cancers13174378"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance Bacillus Calmette-Gu\u00e9rin immunotherapy for recurrent Ta, T1, and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","article-title":"Intermediate-risk non-muscle-invasive bladder cancer: Updated consensus definition and management recommendations from the International Bladder Cancer Group","volume":"5","author":"Tan","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Jocham","year":"2003","journal-title":"J. Urol."},{"key":"ref_24","unstructured":"Japanese Urological Association (2025, November 03). Bladder Cancer Clinical Practice Guidelines 2019 [Supplemented Edition]. Available online: https:\/\/www.urol.or.jp\/lib\/files\/other\/guideline\/39_bladder_cancer_2019.pdf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"15268","DOI":"10.1038\/s41598-019-51889-0","article-title":"BCG instillation versus radical cystectomy for high-risk NMIBC with squamous\/glandular histologic variants","volume":"9","author":"Suh","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/iju.14105","article-title":"Practice pattern of non-muscle invasive bladder cancer in Japan, Korea and Taiwan: A web-based survey","volume":"26","author":"Choo","year":"2019","journal-title":"Int. J. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Matulay, J.T., Tabayoyong, W., Duplisea, J.J., Chang, C., Daneshmand, S., Gore, J.L., Holzbeierlein, J.M., Karsh, L.I., Kim, S.P., and Konety, B.R. (2020). Variability in adherence to guidelines-based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology members. Urol. Oncol., 38.","DOI":"10.1016\/j.urolonc.2020.04.026"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Aghamir, S.M.K., Khatami, F., Farrokhpour, H., Oliveira Reis, L., Ahmadi Pishkuhi, M., and Mohammadi, A. (2022). Oncologic outcomes of Bacillus Calmette-Gu\u00e9rin therapy in elderly patients with non-muscle-invasive bladder cancer: A meta-analysis. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0267934"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6230409","DOI":"10.1155\/2019\/6230409","article-title":"Clinical spectrum of complications induced by intravesical immunotherapy of Bacillus Calmette-Gu\u00e9rin for bladder cancer","volume":"2019","author":"Liu","year":"2019","journal-title":"J. Oncol."},{"key":"ref_31","first-page":"605","article-title":"Field cancerization in the bladder: Clonal expansion of mutated urothelium and bladder cancer risk","volume":"12","author":"McDonald","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.juro.2016.03.151","article-title":"A 10-item checklist improves reporting of critical procedural elements during transurethral resection of bladder tumor","volume":"196","author":"Anderson","year":"2016","journal-title":"J. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines: Non-muscle-invasive bladder cancer","volume":"119","author":"Woldu","year":"2017","journal-title":"BJU Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.juro.2013.08.022","article-title":"The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical Bacillus Calmette-Gu\u00e9rin","volume":"191","author":"Sfakianos","year":"2014","journal-title":"J. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0022-5347(05)01002-5","article-title":"The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: A prospective, randomized clinical trial","volume":"175","author":"Divrik","year":"2006","journal-title":"J. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Jiang, S., and Redelman-Sidi, G. (2022). BCG in Bladder Cancer Immunotherapy. Cancers, 14.","DOI":"10.3390\/cancers14133073"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.20517\/2394-4722.2017.25","article-title":"Systemic humoral responses of non-muscle-invasive bladder cancer during BCG treatment: Less is more","volume":"3","author":"Videira","year":"2017","journal-title":"J. Cancer Metastasis Treat"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"102445","DOI":"10.1016\/j.clgc.2025.102445","article-title":"A Systematic Review and Meta-Analysis of the Effectiveness and Safety of Immune Checkpoint Inhibitors in Patients With BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer","volume":"23","author":"Soliman","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JU.0000000000004020","article-title":"Efficacy of Intravesical Nadofaragene Firadenovec for Patients with Bacillus Calmette-Gu\u00e9rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up from a Phase 3 Trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J. Urol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/3\/532\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T05:16:59Z","timestamp":1770527819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/3\/532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cancers18030532"],"URL":"https:\/\/doi.org\/10.3390\/cancers18030532","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]}}}